NCT03734601View on ClinicalTrials.gov

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

December 26, 2019

Study Completion Date

November 17, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative DisorderChronic Lymphocytic LeukemiaB-cell LymphomaT-cell LymphomaNon Hodgkin LymphomaHodgkin LymphomaChronic Myelomonocytic Leukemia
Interventions
RADIATION

Total body irradiation (TBI)

Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning

DRUG

Anti-thymocyte globulin (ATG)

Given intravenous (IV), Dose 1.5 mg/kg x 5 days

DRUG

Tacrolimus

Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)

DRUG

Mycophenolate mofetil (MMF)

Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.

RADIATION

Total lymphoid irradiation (TLI)

9 x 120 cGy over 11 days

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter